1. Evaluating BTK Inhibitors in CLL

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. BTK Inhibitors in CLL On-Label and Off-Label Uses

4. RESONATE Ibrutinib in Previously Treated CLL

5. RESONATE Safety Profile of Ibrutinib in Previously Treated CLL

6. RESONATE-2 Ibrutinib in Previously Untreated CLL

7. Toxicities With Ibrutinib in RESONATE-2

8. In Vitro Off-Target Effects of Ibrutinib

9. Atrial Fibrillation and Ventricular Arrhythmias

10. Ibrutinib-Associated Bleeding Expert Observations and Suggestions

11. Ibrutinib-Associated Hypertension Expert Observations and Suggestions

12. Development of Ibrutinib Resistance

13. Acalabrutinib A Selective BTK Inhibitor

14. ACE-CL-001 Acalabrutinib in R/R CLL

15. Toxicities Associated With Acalabrutinib

16. Acalabrutinib in Ibrutinib-Intolerant Patients

17. Acalabrutinib in Front-Line CLL

18. Choosing Between BTK Inhibitors Guideline Recommendations and Expert Opinion

19. ELEVATE CLL R/R Acalabrutinib vs Ibrutinib in Previously Treated High-Risk CLL

20. Other Supportive Care Issues

21. Next-Generation BTK Inhibitors

22. Combination Approaches A Potential Pathway to Fixed-Duration Therapy?

23. Key Takeaways

24. Abbreviations

25. Abbreviations (cont)